Focus: Galderma is a Dallas-based specialty pharmaceutical company focused on dermatological consumer products and drugs, with a concentrated portfolio anchored by legacy rosacea and acne treatments.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Galderma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Galderma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Galderma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship asset representing 36% of revenue; exclusive doxycycline formulation with mechanism unknown, faces patent cliff in 3 years.
Peak-stage cream with extended LOE (2034) providing mid-term revenue runway and market differentiation in rosacea.
Generic corticosteroid facing post-LOE erosion; limited pricing power and differentiation.
Vitamin D analog ointment with LOE approaching; moderate revenue contributor in specialized indications.
Peak-stage topical with 7-year patent runway (LOE 2031); alpha-2 agonist vasoconstrictor for rosacea flushing.
Selective RAR-gamma agonist with 9-year exclusivity runway; differentiated retinoid mechanism in competitive acne market.
Potent topical corticosteroid shampoo facing LOE; generic competition limits differentiation.
Vaginal metronidazole gel with extended exclusivity (LOE 2032); niche indication outside core dermatology.
24 discontinued, 38 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
No recent FDA warnings, WARN Act filings, or drug shortages identified; operational and compliance risk profile appears low.
+3 more products